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Background: Resuscitation following bupivacaine-induced cardiovascular collapse is difficult and often refractory 
to conventional treatment. This study was performed to assess the effect of insulin on bupivacaine-induced 
cardiovascular collapse in pentobarbital-anesthetized rabbits. 
Methods: Bupivacaine was administered at 0.75 mg/kg/min until the heart rate decreased to 65 beats/min. A bolus 
of regular insulin (2 U/kg) was administered intravenously at the bupivacaine infusion endpoint (BIE) in the insulin 
group (n = 8), and 2 mL of 0.9% NaCl was administered to the control group (n = 8). 
Results: All animals in the insulin group survived and four animals died in the control group. Arrythymia was rare 10 
minutes after the BIE in the insulin group. 
Conclusions: Bupivacaine-induced cardiovascular collapse can be effectively reversed with an insulin injection, 
probably through facilitation of cardiac conduction and contraction. (Korean J Anesthesiol 2011; 61: 493-498)
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Introduction
Since cardiotoxicity induced by bupivacaine was first reported 
by A1bright [1] and has been widely used in the areas of pain 
control and obstetrics, it is known to be refractory to cardio  pul-
monary resuscitation with epinephrine. Thereafter, numerous 
studies were performed to investigate the mechanism and 
treatment modalities of bupivacaine-induced cardio  toxicity 
[2-7]. This cardiotoxicity is caused by inhibiting heart muscle 
conduction and contractility. Bupivacaine inhibits cardiac 
conduction by decreasing upstroke velocity of action potentials 
through blockage of myocardial voltage-sensitive sodium 
channels [2], by delaying repolarization through the inhibition 
of transient outward K
+ current (Ito), and by prolonging 
action potential duration [3]. In addition, bupivacaine inhibits 
myocardial contractility by suppressing Ca
2+ excretion from the 
sarcoplasmic reticulum [4].
Insulin activates Ito and Ca
2+ transport into the sarcoplasmic 
reticulum and increases cytoplasmic glucose concentration 
and mitochondrial pyruvate availability [8,9]. Experimental 
studies in dogs have demonstrated that administering insulin 
successfully treats severe bupivacaine-induced cardiotoxicity 
and that heart rate, QTc, PR interval, QRS duration, and cardiac 
output improve more rapidly in an insulin-treated group than 494 www.ekja.org
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those in a control group [10-12].
Cardiac contraction and ventricular conduction is inhibited 
severely during a fast heart rate, when bupivacaine concentration 
increases and QRS duration is prolonged [2,5]. We presumed 
that a rabbit is a more suitable animal than a dog for severe 
bupivacaine-induced cardiac toxicity because of its faster heart 
rate. Therefore, we evaluated the effect of insulin on bupiva-
caine-induced cardiac toxicity and cardiac conduction blockage 
in terms of hematological and electrocardiogram (ECG) 
parameters in rabbits. 
Materials and Methods
This experimental study protocol was approved by the Animal 
Care and Use Committee of Seoul National University College of 
Medicine.
Sixteen New Zealand white rabbits, weighing 2.5 kg, were 
used. After an intramuscular injection of ketamine (15 mg/kg) 
and xylazine (10 mg/kg), a venous route was established in the 
ear marginal vein, and endotracheal intubation was performed. 
Vecuronium (0.1 mg/kg) was intravenously injected, and a 
Servo 900 C device (Siemens, Solna, Sweden) was connected 
to the tracheal tube. Respiratory rate and tidal volume were 
controlled at a PaCO2 of 40 mmHg. Anesthesia was maintained 
by continuous intravenous administration of pentobarbital (3-5 
mg/kg/h) and injections of vecuronium (0.01 mg/kg) every 30 
minutes.
The right carotid artery was incised, and a 20 G arterial 
catheter was inserted to continuously measure blood pressure 
and to collect blood samples. A central venous catheter was 
inserted into the right jugular vein to measure central venous 
pressure and to administer fluids. Limb ECG leads were attached 
to monitor heart rate and arrhythmias in lead II. A 12-lead 
resting ECG analysis system (MAC 8 Marquette, Los Angeles, 
CA, USA) was used.
Baseline hematological data and a blood gas analysis were 
collected after a 10-minute stabilization period, and then 
pentobarbital /bupivacaine was intravenously administered. 
In a preliminary experiment, the infusion velocity of bupi-
vacaine was 0.5-1.0 mg/kg/min, and the optimum infusion 
velocity was 0.75 mg/kg/min, based on the finding that 
hematological changes were more predictable (data are not 
shown). 
We found that the rabbits had difficulty awaking spon-
taneously from the anesthesia with an approximate heart rate 
of 65/min. At that time, mean blood pressure was almost 20 
mmHg, which was determined to be the cardiac depression 
point (bupivacaine infusion endpoint, BIE) and the death 
rate was 50%. The intravenous infusion of bupivacaine and 
pentobarbital was stopped at the BIE, and the rabbits were 
divided into two groups; those that were administered regular 
insulin (2 U/kg) mixed with 2 ml of 9% NaCl solution (insulin 
group) and those that were administered the same volume of 
0.9% NaCl solution (control group). Hematological data, such 
as mean arterial blood pressure and heart rate and ECG, were 
obtained every 5 minutes between the starting point and the 
BIE. An arterial blood gas analysis and electrolytes (Na
+, K
+, 
Ca
2+), blood glucose, and blood drug concentrations were 
conducted every 10 minutes. These data were obtained again 
at the BIE. The same collection procedures were performed for 
30 minutes after the BIE. The arterial blood samples collected 
to measure blood drug concentration were centrifuged at 2,500 
rpm for 20 minutes, and the plasma was separated and stored at 
-70
oC. The blood bupivacaine concentration was measured by 
high performance liquid chromatography. Sodium bicarbonate 
(2 mEq/kg/h) was continuously administered intravenously 
to prevent acidosis during the experiment, and 2 ml of 50% D/
W was administered if blood glucose was ≤ 60 mg/dl. Survival 
was defined when sinus rhythm occurred and heart rate/mean 
blood pressure recovered to baseline values after BIE for 30 
min. All rabbits were sacrificed by infusing 40 mEq KCl after 
completing the experiment.
Data are expressed as mean ± SD. Survival rate and frequency 
of cardiac arrythmia between the two groups was compared 
using Fisher’s exact test. Differences in body weight and blood 
hemoglobin concentration measured at the start of the experi-
ment and the total volume of infused bupivacaine and bupi-
vacaine concentration at the BIE were analyzed using the 
unpaired t-test. A repeated-measures analysis of variance was 
used to compare hematological data and bupivacaine concen-
trations at different time points within the same group. Post 
hoc analyses were performed using the Bonferroni-adjusted 
test. A P value < 0.05 was considered statistically significant. 
All statistical analyses were performed using SPSS version 12.0 
(SPSS Inc, Chicago, IL, USA).
Results
No significant differences were observed for body weight or 
hemoglobin concentration between the two groups at the start 
of the experiment. No significant differences in the time interval 
between the start point and the BIE, the volume of infused 
bupivacaine, or bupivacaine concentration at the BIE were 
observed between the two groups. No significant differences 
in arrhythmia, heart rate, mean blood pressure, PR interval, or 
QRS duration were observed between the two groups from the 
start of the experiment to the BIE (Tables 1, 2, and 3).
The BIE heart rate and mean arterial blood pressure decreased 
significantly as bupivacaine was infused, and the PR interval 
and QRS duration increased significantly compared to baseline 495 www.ekja.org
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values (P < 0.05). All rabbits showed a normal sinus rhythm 
at the start, but the PR interval and QRS duration increased as 
bupivacaine was infused. QRS duration increased earlier than 
the PR interval, and the changes in S wave amplitude appeared 
earliest in the QRS complex (Fig. 1). PR interval increased only 
at the BIE in the control group, whereas it increased for up to 20 
minutes after the BIE in the insulin group, compared to baseline 
values. QRS duration increased for up to 5 minutes after the BIE 
in the control group, whereas it increased for up to 25 minutes 
after the BIE in the insulin group (Table 3). Heart rate decreased 
significantly for up to 15 minutes after the BIE in the insulin 
group compared to baseline values (P < 0.05) (Table 3).
Table 1. Baseline Data of the Experimental Rabbits 
Parameter
Control  group 
(n = 8)
Insulin group 
(n = 8)
P values
Weight on baseline (kg)
Hb on baseline (g/dl)
Amount of bupivacaine     
  infused (mg) to BIE
Plasma bupivacaine 
  concentration on BIE 
  (mcg/ml)
Time to BIE (sec)
Number of survival
2.7 ±  0.4
10.3 ± 0.8
12 ± 8.2
16.5 ± 4.4
1,003 ± 741.7
4
2.7 ± 0.3
10.5 ± 1.0
15 ±  14.6
21.6 ± 15.3
1,219 ± 1,174.2
8
Ns
Ns
Ns
Ns
Ns
0.038*
Values are mean ± SD. Ns: non-significant, BIE: bupivacaine infusion 
endpoint. *P < 0.05. 
Table 2.  Number of Animals with Arrhythmias
Arrhythmia
Control  
group 
(n = 8)
Insulin 
group  
(n = 8)
P values
Before BIE 
After BIE 
Sinus bradycardia c
  QRS widening
Bigemy
PVC
AIVR
Junctional rhythm
Polymorphic ventricular
  tachycardia
Polymorphic ventricular 
  tachycardia
PVC
AV Block
AIVR
Asystole, EMD
4
2
1
0
0
1
5
4
2
1
4
5
1
1
1
1
0
6
3
2
0
0
Ns
Ns
Ns
Ns
Ns
Ns
Ns
Ns
Ns
Ns
0.038*
PVC: premature ventricular contractions, AIVR: accelerated idio  ven-
tricular rhythm, EMD: electromechanical dissociation, BIE: bupi  -
vacaine infusion endpoint, Ns: non-significant. *P < 0.05 is signifi  cant.
Table 3. Comparison of Hemodynamic Data between the Control and Insulin Groups
Group Base BIE 5 min 10 min 15 min 20 min 25 min 30 min
HR
MAP (mmHg)
PR interval
QRS duration
Plasma bupivac
  conc. (mcg/ml)
Control
Insulin
Control
Insulin
Control
Insulin
Control
Insulin
Control
Insulin
144.5 ± 25.4
(N = 8)
157.0 ± 18.4
(N = 8)
67.5 ± 16.3
(N = 8)
60.7 ± 12.3
(N = 8)
86.6 ± 12.9
(N = 8)
81.7 ± 9.0
(N = 8)
34.6 ± 5.8
(N = 8)
39.1 ± 6.4
(N = 8)
0
0
65.7 ± 5.28*
(N = 8)
66.0  ± 2.9*
18.8 ± 4.9*
(N = 8)
22.0 ± 6.7*
104.8 ± 19.8*
(N = 5)
112.2 ± 17.2*
(N = 8)
63.8 ± 18.1*
(N = 6)
71.6 ± 10.0*
(N = 8)
16.5 ± 3.4*
(N = 8)
21.6 ± 5.7*
81.0 ± 14.6*
(N = 6)
101.6 ± 21.8*
21.5 ± 4.3*
(N = 6)
32.3 ± 14.5*
120.7 ± 16.9
(N = 4) 
119.7 ± 18.8*
(N = 8)
62.5 ± 13.2*
(N = 4)
73.1 ± 9.4*
(N = 8)
105.7  ± 32.5*
(N = 5)
142.3 ± 43.1
29.2 ± 2.7*
(N = 5)
36.5 ± 14.4
109.7 ± 23.3
(N = 4)
126.7 ± 15.5*
(N = 6)
73.2 ± 25.8
(N = 4)
63.4 ± 13.8*
(N = 6)
3.8 ± 2.8*
(N = 4)
2.8 ± 1.3*
128.0  ± 37.0*
(N = 4)
162.7  ± 48.3
39.2 ± 5.0
(N = 4)
44.5 ± 19.0
113.2 ± 22.5
(N = 4)
120.2 ± 15.5*
(N = 6)
53.0 ± 10.2
(N = 4)
58.5 ± 15.1*
(N = 7)
149.2  ± 40.8
(N = 4)
179.5 ± 39.2
44.5 ± 5.2
(N = 4)
47.8 ± 12.7
107.5 ± 18.4
(N = 3)
113 ± 18.1*
(N = 6)
50 ± 10.4
(N = 4)
53.3 ± 14.3*
(N = 7)
2.0 ± 1.2*
(N = 4)
1.7 ± 1.1*
186.0  ± 18.4
(N = 4)
178.5  ± 36.2
49.2 ± 22.8
(N = 4)
51.7 ± 10.4
105 ± 17.3
(N = 3)
106.6 ± 20.6
(N = 6)
42.5 ± 7.6
(N = 4)
54.1 ± 14.3*
(N = 8)
197.0  ± 24.1
(N = 4)
178.7  ± 29.4
47.5 ± 18.1
(N = 4)
48.8 ± 13.0
105 ± 10.8
(N = 2)
102.5 ± 20.4
(N = 6)
41.2 ± 6.2
(N = 4)
43.5 ± 10.0
(N = 7)
1.3 ± 0.7*
(N = 4)
1.2 ± 1.0*
Values are mean ± SD. MAP: mean arterial pressure, HR: heart rate, BIE: bupivacaine infusion endpoint. *P < 0.05  vs.  baseline. 
Fig. 1. Electrocardiographic changes induced by bupivacaine infusion 
in rabbits. Lead II electrocardiogram recorded at 25 mm/s. (A) During 
the baseline period, the values were: heart rate, 190 bpm/min; PR 
interval, 80 ms; QRS duration, 40 ms; QTC interval, 269 msec. (B) 
Bupivacaine at a concentration of 20.2 μg/ml administered at the 
bupivacaine infusion endpoint (BIE) resulted in the following alte-
rations: heart rate, 67 bpm/min; PR interval, 140 ms; QRS duration, 
62 ms; QTC interval, 344 msec.496 www.ekja.org
Vol. 61, No. 6, December 2011 Insulin effect on bupivacaine-induced cardiotoxicity 
Table 2 shows the cardiac arrhythmias that occurred before 
and after the BIE. The most common cardiac arrhythmia was 
sinus bradycardia associated with QRS widening (n = 4 in 
the control group and n = 5 in the insulin group) (Fig. 1). All 
rabbits in the control group, which showed electromechanical 
dissociation (n = 2) and asystole (n = 2), died at 1, 4, 8, and 
17 minutes after the BIE. Severe cardiac arrhythmias, such as 
electromechanical dissociation and asystole, occurred less 
frequently in the insulin group (P < 0.05). Four of eight rabbits 
in the control group survived, whereas all eight rabbits in the 
insulin group survived (P < 0.05).
Blood bupivacaine concentration decreased abruptly 10 
minutes after the BIE, and no significant differences in the con-
centration were observed at different time points between the 
two groups (Table 3). The arterial blood gas analysis revealed 
no significant differences in pH, PaCO2, or PaO2 between the 
two groups at different time points, and the values were within 
the normal range in both groups. Blood Na
+ concentration 
was not significantly different either. Blood Ca
2+ concentration 
decreased at the BIE compared to baseline values in the 
control group and decreased for up to 10 minutes after the BIE 
in the insulin group, but the differences were not statistically 
significant. Blood K
+ concentration, measured 10 minutes after 
the BIE, decreased more significantly in the insulin group than 
that in the control group (Table 4). Although blood glucose 
concentration in the insulin group increased 10 minutes after 
the BIE compared to that in the control group, blood glucose 
concentration was not significantly different between the two 
groups. Hyperglycemia ≥ 300 mg/dl occurred in two rabbits in 
the control group. Hypoglycemia ≤ 60 mg/dl occurred in one 
rabbit in the insulin group, which received 2 ml of 5% D/W 
solution.
Discussion
We evaluated the effect of insulin on bupivacaine-induced 
cardiotoxicity in rabbits. Four of the eight rabbits in the control 
group survived after the BIE, whereas all eight rabbits in the 
insulin group survived. Severe arrhythmias, such as electro-
mechanical dissociation and asystole, occurred after the 
BIE in two rabbits each in the control group, whereas these 
arrhythmias occurred less frequently in the insulin group. 
However, the heart rate and mean blood pressure recovery 
patterns were not significantly different between the groups. 
Previous studies on dogs have demonstrated that insulin rapidly 
improves heart rate, QTc, PR interval, and QRS duration and 
significantly increases contractility during bupivacaine-induced 
cardiotoxicity [10-12]. In our study, the improvement in heart 
rate, PR interval, and QRS duration was not significantly different 
between the insulin and control groups, but the frequency of 
severe arrhythmias was significantly lower in the insulin group. 
Based on these results, insulin may decrease the frequency of 
severe arrhythmias and subsequently increase survival rate. 
Further studies are needed to confirm this result.
Humans, dogs, and rabbits have similar cardiac contraction 
mechanisms [13]. Considering that rabbits have a more rapid 
heart rate than dogs, rabbits were used to evaluate the effect 
of insulin on heart rate. Our pilot study of rabbits determined 
that spontaneous wakening from anesthesia was difficult at an 
approximate heart rate of 65/min, so the BIE was determined 
to be 65/min. At this BIE, mean blood pressure was 20.2 ± 9.6 
mmHg in the control group and 22.6 ± 8.9 mmHg in the insulin 
group, but the difference was not statistically significant (Table 1). 
Bupivacaine-induced cardiotoxicity is a conduction disorder 
caused by inhibiting sodium channels within the ventricle, 
Table 4. Change in Arterial Blood Gases, Serum Electrolytes, and Plasma-Glucose Concentrations between the Control and Insulin Groups
Group Base BIE 10 min 20 min 30 min
PH
PaO2 (mmHg)
PaCO2 (mmHg)
Na
+ (mEq/L)
K
+ (mEq/L)
Ca
2+ (mEq/L)
Glucose (mg/dl)
Control
Insulin
Control
Insulin
Control
Insulin
Control
Insulin
Control
Insulin
Control
Insulin
Control
Insulin
7.4 ± 0.07
7.41 ± 0.07
491.0 ± 49.0
494.3 ± 67.9
41.0 ± 10.5
34.1 ± 5.4
143.1 ± 1.8
146.2 ± 9.6
3.21 ± 0.4
3.10 ± 0.76
2.70 ± 0.29
2.66 ± 0.46
184 ± 84
164 ± 57
7.5 ± 0.18
†
7.41 ± 0.18
479.4 ± 82.6
446.0 ± 107.8
32.0 ± 17.8
35.8 ± 12.6
152.6 ± 11.7
146 ± 4.6
3.28 ± 0.17
2.97 ± 0.50
2.15 ± 0.49
†
2.24 ± 0.45
†
206 ± 137
193 ± 69
7.47 ± 0.20
†
7.36 ± 0.10
479.4 ± 82.6
507.3 ± 78.4
32.4 ± 12.9
39.1 ± 10.7
†
148.9 ± 3.6
146.3 ± 4.5
3.30 ± 0.66
2.54 ± 0.44*
2.24 ± 0.35
2.09 ± 0.44
†
190.7 ± 139
205 ± 45
†
7.41 ± 0.09
7.36 ± 0.09
527.2 ± 18.1
503.3 ± 73.0
39.3 ± 4.5
40.1 ± 10.3
†
148.8 ± 3.6
147.4 ± 4.0
3.00 ± 0.14
2.62 ± 0.69
2.20 ± 0.35
2.11 ± 0.38
176 ± 144
151 ± 38
7.44 ± 0.05
7.37 ± 0.10
538.6 ± 5.6
448.1 ± 129.2
35.3 ± 4.5
40.5 ± 9.9
†
149.1 ± 4.0
147.9 ± 3.3
3.10 ± 0.10
2.77 ± 0.76
2.34 ± 0.93
2.11 ± 0.39
154 ± 144
132 ± 54
Values are mean ± SD. BIE: bupivacaine infusion endpoint. Control group: base BIE (n = 8), 10 min (n = 5), 20 min (n = 4), 30 min (n = 4). *P < 0.05 
vs. control group. 
†P < 0.05 vs. baseline.497 www.ekja.org
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which is revealed as a prolongation of PR interval and QRS 
widening [14,15]. In our study, PR interval and QRS widening 
increased at the BIE compared to those at baseline. During 
QRS widening, the S-wave amplitude in lead III increased first, 
which was similar to the result of a previous study in dogs by 
Jeong et al. [16]. They reported that changes in S-wave ampli-
tude reflect a decrease in cardiac output and can be used as 
an indicator of bupivacaine-induced cardiotoxicity. However, 
further studies are needed to determine whether cardiac output 
is related to S-wave amplitude. PR interval and QRS widening 
were not normalized in either group and increased for up to 30 
minutes after the BIE but recovered to sinus rhythm. Persistent 
prolongation of the PR interval may have been related to 
the decrease in blood K
+ concentration in the insulin group. 
However, the difference in blood K
+ concentration between 
the two groups was not statistically significant because of early 
death of animals in the control group and because the PR 
interval was not checked in both groups. Because bupivacaine 
binds to sodium, potassium, and calcium channels within the 
myocardium in a fast-in, slow-out manner [2], a conduction 
disorder may persist for a longer time, even if bupivacaine 
concentration decreases. Additionally, mean blood pressure 
decreases due to a bupivacaine-induced myocardial contrac-
tility disorder, subsequently decreasing coronary perfusion 
pressure and producing numerous ischemic areas in the 
my  ocardium. A previous study in rabbits demonstrated that 
bupi  vacaine induces atrioventricular block and re-entrant 
ven  tri  cular dysrhythmias by inhibiting conduction at atrial, 
ventricular, and atrioventricular levels [17]. In our study, con-
duction block and re-entrant ventricular dysrhythmias occurred 
as in previous studies.
Insulin activates Ito and Ca
2+ transport into the sarcoplasmic 
reticulum and increases cytoplasmic glucose concentration and 
mitochondrial pyruvate availability [8,9]. Furthermore, insulin 
facilitates potassium transport from the extracellular to the 
intracellular space through an Na
+-K
+ pump in skeletal muscles 
and the liver, subsequently decreasing blood K
+ concentration. 
This effect of insulin is proportional to its infused volume, 
occurs within 10 minutes of administration, and lasts more 
than 60 minutes [18]. This may explain our result that blood K
+ 
concentration was lower in the insulin group than that in the 
control group 10 minutes after insulin administration. Although 
the half-life of insulin is 5 minutes when injected intravenously, 
its pharmacologic effect lasts longer than the half life because 
it binds strongly to receptors [11]. In our study, only blood 
glucose concentration at the 10 min BIE increased in the insulin 
group compared to baseline values, but no other significant 
differences were observed between the two groups. This pheno-
menon is related to the blood glucose increase during acute 
cardiopulmonary resuscitation [19].
Bupivacaine-induced cardiotoxicity increases in the presence 
of acidosis or hypoxia [20]. In our study, the amount of sodium 
bicarbonate was controlled during intravenous infusion based 
on the arterial blood gas analysis results. As a result, metabolic 
acidosis did not occur in any rabbit, and no significant difference 
in arterial pH was observed between the two groups at different 
time points. We also prevented hypoxia by mechanically 
ventilating with 100% oxygen. We attempted to evaluate the 
effect of bupivacaine on conduction but found no significant 
difference in the recovery of heart rate and mean blood 
pressure. Because the duration of insulin action is >1 hour, 
additional studies for ≥ 1 hour are needed to confirm our results.
In conclusion, our results suggest that insulin may decrease 
the frequency of cardiac arrhythmias and, thus, increase survival 
in rabbits with bupivacaine-induced cardiotoxicity.
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